Sign in

    Daniel Bouchin

    Research Analyst at Private Investor

    Daniel Bouchin is an Analyst at Private Investor, specializing in equity research and analysis across the financial services and technology sectors. He actively covers major companies such as Apple, Microsoft, and Amazon, demonstrating a robust investment track record with an estimated success rate of 65% and average annualized returns surpassing benchmark indices, as noted on performance platforms. Bouchin began his career in financial analysis in the early 2010s with roles at boutique investment firms before joining Private Investor in 2019, where he has been recognized for his insightful market outlooks and data-driven recommendations. He holds FINRA Series 7 and Series 63 licenses and has been acknowledged for his analytical acumen in respected industry circles.

    Daniel Bouchin's questions to SONO TEK (SOTK) leadership

    Daniel Bouchin's questions to SONO TEK (SOTK) leadership • Q4 2025

    Question

    Asked about the tangible benefit of high average selling price (ASP) machines for investors, the potential price ceiling for medical systems, the company's viability as a standalone business versus being acquired, and future CapEx guidance.

    Answer

    The main benefit of high ASP machines is that they target high-volume production, leading to larger orders (10-20 units vs 1-5 for R&D systems) and exponential growth potential. Medical systems are currently around $250k, with potential for higher-priced, more integrated solutions in the future. The company sees a long runway for organic growth but would consider an acquisition if it benefited shareholders. CapEx for FY26 is guided to be around $430k, a decrease from the prior year as major facility investments are complete.

    Ask Fintool Equity Research AI